Image For Activity Cover
Electrophysiological Manifestations of Cardiac Amyloidosis (JACC: CardioOncology State-of-the-Art Review October 2021-1)
Electrophysiological Manifestations of Cardiac Amyloidosis JACC: CardioOncology State-of-the-Art Review

Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy caused by the extracellular deposition of amyloid fibrils in the myocardium. Although cardiac amyloidosis patients primarily present with heart failure symptoms, arrhythmias and conduction system disease are frequently encountered. Atrial fibrillation (AF) is observed in up to 70% of patients at the time of diagnosis, and patients typically have controlled ventricular rates caused by concomitant conduction system disease. Thromboembolic risk is particularly high in patients with CA and AF, and left atrial thrombi have been observed even in the absence of clinically diagnosed AF. Atrioventricular nodal and infra-Hisian disease are common, and permanent pacemakers are frequently required. The use of implantable cardioverter-defibrillators in this population is controversial. This review summarizes the published data and therapeutic strategies surrounding arrhythmias and conduction system disease with the goal of aiding clinicians managing the clinical complexities of CA.


JACC CardioOncology Editor-in-Chief and CME Editor
Bonnie Ky, MD, MSCE, FACC

Authors
Eoin Donnellan MD
Jack Hartnett MB, BCh, BAO
Oussama Wazni MD
Wael Jaber MD

Important Dates

Date of Release: October 19, 2021    
Term of Approval/Date of CME/MOC/ECME Expiration: October 18, 2022 

Summary
Availability: On-Demand
Expires on Oct 18, 2022
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Android App Download IOS App Download Powered By